98%
921
2 minutes
20
Small pulmonary nodules are most often managed by surveillance imaging with computed tomography (CT) of the chest, but the optimal frequency and duration of surveillance are unknown. The Watch the Spot Trial is a multicenter, pragmatic, comparative-effectiveness trial with cluster randomization by hospital or health system that compares more- versus less-intensive strategies for active surveillance of small pulmonary nodules. The study plans to enroll approximately 35,200 patients with a small pulmonary nodule that is newly detected on chest CT imaging, either incidentally or by screening. Study protocols for more- and less-intensive surveillance were adapted from published guidelines. The primary outcome is the percentage of cancerous nodules that progress beyond American Joint Committee on Cancer seventh edition stage T1a. Secondary outcomes include patient-reported anxiety and emotional distress, nodule-related health care use, radiation exposure, and adherence with the assigned surveillance protocol. Distinctive aspects of the trial include: ) the pragmatic integration of study procedures into existing clinical workflow; ) the use of cluster randomization by hospital or health system; ) the implementation and evaluation of a system-level intervention for protocol-based care; ) the use of highly efficient, technology-enabled methods to identify and (passively) enroll participants; ) reliance on data collected as part of routine clinical care, including data from electronic health records and state cancer registries; ) linkage with state cancer registries for complete ascertainment of the primary study outcome; and ) intensive engagement with a diverse group of patient and nonpatient stakeholders in the design and execution of the study.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1513/AnnalsATS.201903-268SD | DOI Listing |
Minerva Surg
September 2025
Unit of Geriatric Medicine, Department of Emergency, Foresea Life Insurance Guangzhou General Hospital, Guangzhou, China -
J Neurooncol
September 2025
Department of Neurosurgery, University of Michigan, Ann Arbor, MI, USA.
Purpose: Frailty measures are critical for predicting outcomes in metastatic spine disease (MSD) patients. This study aimed to evaluate frailty measures throughout the disease process.
Methods: This retrospective analysis measured frailty in MSD patients at multiple time points using a modified Metastatic Spinal Tumor Frailty Index (MSTFI).
J Cancer Res Clin Oncol
September 2025
Institute for Community Medicine, Section Epidemiology of Health Care and Community Health, University Medicine Greifswald, Greifswald, Germany.
Purpose: The German sector-based healthcare system poses a major challenge to continuous patient monitoring and long-term follow-up, both essential for generating high-quality, longitudinal real-world data. The national Network for Genomic Medicine (nNGM) bridges the inpatient and outpatient care sectors to provide comprehensive molecular diagnostics and personalized treatment for non-small cell lung cancer (NSCLC) patients in Germany. Building on the established nNGM infrastructure, the DigiNet study aims to evaluate the impact of digitally integrated, personalized care on overall survival (OS) and the optimization of treatment pathways, compared to routine care.
View Article and Find Full Text PDFJ Thorac Oncol
September 2025
Institut du Thorax Curie-Montsouris, Paris, France; Paris-Saclay University, UVSQ-Versailles, France.
Introduction: Amivantamab plus lazertinib significantly improved progression-free and overall survival versus osimertinib in patients with previously untreated, EGFR-mutant advanced NSCLC. EGFR-targeted therapies are associated with dermatologic adverse events (AEs), which can affect quality of life (QoL). COCOON was conducted to assess prophylactic management and improve treatment experience.
View Article and Find Full Text PDFHeart Rhythm
September 2025
Translational Cardiology Group, Health Research Institute, Santiago de Compostela, Spain; CIBERCV, Madrid, España. Electronic address:
Background: High % of low-voltage area (LVA), a surrogate of scar, is associated with atrial fibrillation (AF) recurrence after pulmonary vein isolation (PVI). Noninvasive biomarkers of LVA are a medical need for PVI decision.
Objective: We aimed to identify the proteome profile of plasma extracellular vesicles (EVs) associated with high % LVA, their cellular origin, and their regulation by hyperglycemia.